HIF prolyl-hydroxylase inhibitor
HIF prolyl-hydroxylase inhibitors are members of a class of new drugs that act on the hypoxia-inducible factor (HIF) pathway. They are being investigated for treatment of anemia, chronic kidney disease, cancer, and for their effects on heart tissue and others. Research conducted in mice suggests that they may increase hippocampal memory by increasing erythropoietin expression.
- Warnecke, C.; Griethe, W.; Weidemann, A.; Jurgensen, J. S.; Willam, C.; Bachmann, S.; Ivashchenko, Y.; Wagner, I.; Frei, U.; Wiesener, M.; Eckardt, K.-U. (2003). "Activation of the hypoxia-inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors". The FASEB Journal. doi:10.1096/fj.02-1062fje.
- Ivan, Mircea (2006). "HIF-PROLYL hydroxylase inhibitors: From basic science to clinical trials" (PDF). MÆDICA - a Journal of Clinical Medicine 1 (2): 67–69. ISSN 1841-9038.
- Nangaku, M.; Izuhara, Y.; Takizawa, S.; Yamashita, T.; Fujii-Kuriyama, Y.; Ohneda, O.; Yamamoto, M.; Van Ypersele De Strihou, C. et al. (2007). "A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against Ischemia". Arteriosclerosis, Thrombosis, and Vascular Biology 27 (12): 2548. doi:10.1161/ATVBAHA.107.148551.
- "FibroGen Reports New Research on Development of HIF Prolyl Hydroxylase Inhibitors Related to Endothelial Progenitor Cells, Anti-Inflammation, Cytoprotection and Erythropoiesis". drugs.com. 2008.
- Adamcio, B; Sperling, S; Hagemeyer, N; Walkinshaw, G; Ehrenreich, H (2010). "Hypoxia inducible factor stabilization leads to lasting improvement of hippocampal memory in healthy mice". Behavioural brain research 208 (1): 80–4. doi:10.1016/j.bbr.2009.11.010. PMID 19900484.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|